News | October 28, 2013

Biosensors Celebrates a Year of Achievement at TCT with Expanded Product Portfolio

stents drug eluting biosensors tct 2012 transcatheter biomatrix neoflex spectrum
October 28, 2013 — Biosensors International’s expanded product portfolio offers physicians a broader range of treatment options to improve patient outcomes.
 
Since the 2012 Transcatheter Cardiovascular Therapeutics annual conference (TCT 2012), the company has revitalized its core offering with the launch of BioMatrix NeoFlex, a drug-eluting stent (DES) with exceptional performance in complex lesions and challenging anatomies. It also expanded its range of dedicated bifurcation stents with Axxess, which designed to treat larger, shorter and wider-angulated bifurcations; complemented its stent portfolio by introducing a range of drug-eluting balloon dilation catheters for the treatment of both coronary and peripheral artery disease as well as introduce BioFreedom, the world’s first polymer-free stent coated with Biolimus A9.
 
In May, Biosensors acquired functional imaging company Spectrum Dynamics, whose expertise will help cath labs determine which patients require a stent without the need for diagnostic angiography. Spectrum Dynamics’s technology is faster than conventional functional imaging, requires less contrast medium to be injected and can deliver up to 10 times the sensitivity and twice the spatial resolution.
  
“We have come further than we could possibly have imagined since last year’s TCT,” said Jeffrey Jump, president, cardiovascular division, Biosensors. “Over the last 12 months, we have revamped the leading biodegradable polymer DES, increased the applications for our specialist bifurcation stent, offered cath labs a wider choice of treatment options with a range of drug-eluting balloons and acquired technology with the potential to fundamentally change the way that interventional cardiology is practiced, so who knows what we can achieve over the next 12 months.”
 
For more information: www.biosensors.com
 

Related Content

Biotronik Symposium Highlights Differing Roles of Drug-Eluting Stents and Magnesium Scaffolds in Clinical Practice
News | Stents Drug Eluting | January 25, 2018
January 25, 2018 – Data presented at the Biotronik-sponsored...
The Abbott Absorb Bioresorbable Vascular Scaffold (BVS) bioabsorbable stent.

The Abbott Absorb Bioresorbable Vascular Scaffold (BVS).

Feature | Stents Drug Eluting | January 17, 2018 | Dave Fornell
There was no shortage of interest in bioresorbable stent technologies at the many sessions offered on this topic or b
Cordis and Medinol Announce FDA Approval of EluNIR Drug-Eluting Stent System
Technology | Stents Drug Eluting | December 13, 2017
Cordis, a Cardinal Health company, and Medinol recently announced U.S. Food and Drug Administration (FDA) approval of...
The Xience Sierra stent.
Technology | Stents Drug Eluting | November 09, 2017
November 9, 2017 — Abbott received European CE mark for Xience Sierra, the newest generation of the company's Xience
Synergy Stent With Shorter DAPT Superior to Bare-Metal Stent in Elderly Patients
News | Stents Drug Eluting | November 06, 2017
November 6, 2017 — Elderly patients undergoing...
Biotronik Orsiro DES Shows Low Five-Year Event Rates
News | Stents Drug Eluting | November 03, 2017
November 3, 2017 — Biotronik's Orsiro...
Three-Month DAPT Non-Inferior for ACS Patients Treated With Combo Dual Therapy Stent

Image courtesy of OrbusNeich

News | Stents Drug Eluting | November 01, 2017
OrbusNeich reported results from the REDUCE trial in the Late-Breaking Clinical Trial session at the 29th annual...
News | Stents Drug Eluting | October 25, 2017
Elixir Medical Corp. announced it will unveil a new metallic drug-eluting stent (DES) platform at this year’s...
Biotronik's Orsiro Drug-Eluting Stent Outperforms Xience in BIOFLOW-V Trial
News | Stents Drug Eluting | September 01, 2017
September 1, 2017 — Biotronik recently announced data from the BIOFLOW-V randomized trial comparing Orsiro and Xience
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting | May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Overlay Init